# The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

> **NCT07285850** · PHASE2,PHASE3 · RECRUITING · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 20 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sequential treatment of bevacizumab combined with atezolizumab (sequential group)
- **DRUG:** Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

## Key facts

- **NCT ID:** NCT07285850
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285850, "The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07285850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*